The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...